Venous thromboembolism (VTE) is the third most common cause of vascular mortality
worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …

Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …

Disseminated intravascular coagulation (DIC) is a systemic activation of the coagulation
system, which results in microvascular thrombosis and, simultaneously, potentially life …

Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …

PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with
cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with …